A review of chemotherapy trials for malignant mesothelioma

Chest
C W RyanN J Vogelzang

Abstract

Treatment of malignant pleural mesothelioma continues to be frustrating regardless of the modality employed. Numerous trials of chemotherapeutic agents have been performed, but until recently, these studies were small and subject to inaccuracies of disease measurement. To our knowledge, no chemotherapeutic regimen has emerged as a standard of care. A review of the literature reveals that small activity against this disease has been shown by the anthracyclines, platinum compounds, and alkylating agents, whereas higher activity has been reported with the antimetabolites. The plant alkaloids have not demonstrated any activity against mesothelioma. Dose-escalated chemotherapeutic regimens may offer an advantage, whereas combination chemotherapy has not shown any benefit over single-agent therapy. Favorable responses have been reported with the administration of intrapleural biological response modifiers. Further trials and the investigation of new agents in the treatment of this disease are necessary.

References

Jul 1, 1992·Investigational New Drugs·C A Hudis, D P Kelsen
Nov 1, 1992·Investigational New Drugs·G FalksonT J Smith
Feb 1, 1991·Investigational New Drugs·H M DhingraW K Hong
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F J van BreukelenO Dalesio
Jan 1, 1991·Cancer Chemotherapy and Pharmacology·A Krarup-Hansen, H H Hansen
Jan 1, 1990·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A S AlbertsL van Zyl
Jan 1, 1990·Cancer Chemotherapy and Pharmacology·N J VogelzangM R Green
May 1, 1989·European Journal of Cancer & Clinical Oncology·J CarmichaelA L Harris
Jun 29, 1989·The New England Journal of Medicine·B T Mossman, J B Gee
Jan 1, 1989·Cancer Chemotherapy and Pharmacology·G Mårtensson, S Sörenson
Jul 6, 1988·Journal of the National Cancer Institute·A S AlbertsL Van Zyl
Jan 1, 1986·Cancer Chemotherapy and Pharmacology·E K MbiddeI E Smith
Nov 1, 1985·Cancer·N ColbertF Chatelet
Jan 1, 1983·Cancer Chemotherapy and Pharmacology·G FalksonH J Lerner
Sep 1, 1995·Seminars in Surgical Oncology·H I Pass, J S Donington
May 1, 1995·Cancer Treatment Reviews·D R FitzpatrickH Bielefeldt-Ohmann
Jun 1, 1995·Chest·D J SugarbakerM J Liptay
Sep 1, 1994·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·D J StewartW K Evans
Sep 1, 1994·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·N TsavarisP Kosmidis
Dec 1, 1993·Australian and New Zealand Journal of Medicine·J W UphamB W Robinson
Feb 1, 1993·Journal of Interferon Research·T I ChristmasB W Robinson
Oct 1, 1960·British Journal of Industrial Medicine·J C WAGNERP MARCHAND
Mar 18, 1965·The New England Journal of Medicine·I J SELIKOFFE C HAMMOND

❮ Previous
Next ❯

Citations

Nov 26, 1999·American Journal of Industrial Medicine·S M LevinM B Lax
Jul 7, 2005·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Patricia J HollenJames J Rusthoven
Jun 5, 2003·Current Oncology Reports·Mazen Y KhalilDong M Shin
Feb 13, 2001·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·C W MulateroR M Rudd
Feb 13, 2001·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·H L KindlerM R Green
Oct 26, 2002·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Long WongRobert A Kratzke
Oct 26, 2002·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·T BerghmansJ P Sculier
Aug 10, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·K FizaziP Ruffié
Mar 22, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G GiacconeB Smit
Jan 25, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J P ArmandT R Evans
Jul 17, 1999·Current Opinion in Pulmonary Medicine·P Astoul
Mar 31, 2000·Current Opinion in Pulmonary Medicine·A M Boylan
Jul 27, 2000·Current Opinion in Pulmonary Medicine·Y C LeeA W Musk
Jul 27, 2000·Current Opinion in Pulmonary Medicine·M R Orenstein, M B Schenker
Sep 15, 2004·Respirology : Official Journal of the Asian Pacific Society of Respirology·Lorriana E Leard, V Courtney Broaddus
Mar 20, 2001·Thorax·UNKNOWN British Thoracic Society Standards of Care Committee
Aug 30, 2003·Thorax·C Parker, E Neville
Jun 28, 2008·American Journal of Respiratory and Critical Care Medicine·Eun-Kee ParkAnthony R Johnson
Mar 30, 2010·Clinical Chemistry and Laboratory Medicine : CCLM·Eun-Kee ParkDeborah H Yates
Feb 12, 2002·Seminars in Oncology·Lambros S Zellos, David J Sugarbaker
Feb 12, 2002·Seminars in Oncology·Karim FizaziNicholas J Vogelzang
Apr 6, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Debby P M van den BogaertRob J van Klaveren
Apr 2, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Robert A KratzkeUNKNOWN Cancer and Leukemia Group B
Aug 24, 1999·Chest·D H StermanS M Albelda
Apr 14, 2009·Clinical Lung Cancer·Daniel A Vorobiof, Keorapetse Mafafo
Dec 19, 2006·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Muzaffer MetintasSelma Metintas
Feb 7, 2006·The International Journal of Biochemistry & Cell Biology·Gianluca FulgenziMaurizio Taglialatela
Feb 13, 2004·International Journal of Cancer. Journal International Du Cancer·Alfonso CatalanoAntonio Procopio
Mar 5, 2016·Expert Review of Anticancer Therapy·Laurel M SchunselaarPaul Baas
Jul 21, 2004·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Axel-Rainer Hanauske
Jul 21, 2004·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Sandra Tomek, Christian Manegold
Jul 12, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·T BerghmansUNKNOWN European Lung Cancer Working Party (ELCWP)
Aug 22, 2003·Clinical Journal of Oncology Nursing·Carol Brueggen, Mary Ellen Cordes
Aug 5, 2009·Journal of Pharmacological Sciences·Hiromi SatoTomohiro Yano

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.